BioNTech Founders Launch New Biotech, Eye FDA Acceptance
Sticking with the science. I find that really impressive. BioNTech founders Uğur Şahin and Özlem Türeci are leaving the biotech they founded to start a new one. Maybe by the time they have something for the clinic, the FDA will be a little more sane about mRNA tech. This too shall pass. https://t.co/t1EWXhCXB3
Senior FDA Official’s Attack Sparks Debate Over Leadership
Gee, who could this "senior FDA official" be? It's a head scratcher. But he might tell Vinay Prasad that thinly veiled attacks against, oh, UniQure, and going off on advisory councils is a great way of keeping the political pot...
FDA Guidance Boosts Biotech, HHS Calls It Fake
Did the FDA’s individualized therapy guidance put a spike in the heart of a startup biotech? Fake news, says the HHS. Yeah, it did, says an insider. Exclusive from @RLCscienceboss and @Jared_Whitlock https://t.co/IN9o4VIp03
Watch Webinar Linking Top 100 Biotech VCs Insights
Here's the link to watch yesterday's webinar on venture capital, a companion to this year's top 100 biotech VCs list with @ChrisDoko Lots of positive feedback here. Post your thoughts. https://t.co/c16y04mFsD
Novo's Missteps Echo Bristol Myers' Strategic Failure
Elizabeth Cairns' piece on $Novo is reminiscent of Bristol Myers' strategic fail against Merck and Keytruda. They were focused on the wrong things, made bad trial design decisions and got stuck in the mud of their own making. Everyone should...
Biotech VC Webinar Launches with Top Experts, Thousands Registered
We'll be gearing up today's webinar on biotech venture capital at the top of the hour. Great guests, great topics. If this is a central issue in your life, tune in. Thousands have signed up already. https://t.co/c16y04mFsD
Makary Slams FDA, Defends Rare Disease Drugs Amid Controversy
You've got to watch this Makary interview on CNBC. He attacks a drug, hits the Old FDA and circles all the wagons around Vinay Prasad, who "loves President Trump" and faces a fatwa (WSJ). Makary is getting major props for...
GSK's New CEO Targets Proven Science, Eyes Obesity Drugs
The FT's report on GSK's $950M deal to buy 35Pharma and its pulmonary arterial hypertension drug includes an interesting unnamed insider's quote that new CEO Luke Miels is going after assets where "the science is relatively settled." Maybe leaning into...
Rival Drug Wins, Costs Us Marketing Gold
That feeling you get when you run a head-to-head study and the rival drug beats you out. Spending a fortune to hand your competitor a marketing message. Sometimes it feels like $NOVO is snake bit. $LLY https://t.co/gGUjl6iqPg
Finalizing Top 100 Biotech VCs, Join 2026 Webinar
We're wrapping up the fact checking process for our annual Top 100 biotech VCs list and prepping for our companion webinar on VC investing in 2026. If this is a topic near and dear to your heart, be sure to...
FDA's Erratic, Unpredictable Decisions Undermine Drug Regulation
The FDA keeps spinning, spinning, spinning round and round. Just what you want from a drug regulator: Erratic decision-making and complete unpredictability. https://t.co/q5abiPwgkW
PET Scans Miss Cancer; System Needs Diagnostic Overhaul
Merkel cell carcinoma log, day #566. Completed my 6th PET scan at Dana-Farber yesterday. The radar, such as it is, doesn’t reflect any Merkel cell carcinoma. Lymph nodes look clean. The more I do PET scans, though, the more I...
Sanofi's Board Ousts Hudson, New CEO Faces Dupixent Gap
So Sanofi's board strikes again. Paul Hudson gets the old Paris boot 6 years after taking on the task of remaking the pipeline. It hasn't gone well. Next: Belen Garijo. She has a few years to get ready for the...
Biotech CEOs Dust Off S‑1s, Hopeful IPO Surge
That blowing sound you hear is from hundreds of biotech ceos blowing the dust off their S-1s, fingers crossed.
Predicting $20B+ Biotech M&A Deal by 2026
One of my #JPM26 predictions for 2026 is that we'll see a $20B-plus M&A deal in biotech. So here's hoping any RevMed deal comes after Monday morning. https://t.co/5pe4ymAILt
Rampart's Fall Highlights Struggles in Legacy Gene Therapy
Ryan's story notes that it's hard to tell exactly what killed Rampart. The faltering gene therapy field, specific scientific challenges, (any internal conflict). Maybe all of the above? No matter what, though, another sign of the cold wind blowing through...